nemoci-sympt/HEMATOLOGIE/myelom/zlepsujici-podpurne-vlivy
Deferasirox
- Induces apoptosis by targeting oncogenic Pyk2/beta-catenin signaling in human multiple myeloma
- Expression of ferroportin correlates with clinical outcomes
- Excess of intracellular iron contributes to
- The pathogenesis of MDS
- Hepatocellular carcinoma
- Iron overload might be also associated with MM pathogenesis
DFX+ bortezomib
- Enhanced cytotoxicity against MM cells
- Combination approaches have been proposed to prevent and/or overcome bortezomib resistance
- Bortezomib-based therapies
- Bring a significant improvement of renal function (major renal response) to 77% of newly diagnosed MM patients
- DFX can be administered to MM patients with or without dose-adjustment protocols during the course of the disease.
- Study has demonstrated that low expression of ferroportin
- Is associated with a poor prognosis in MM
- Might be related to increased levels of intracellular iron that contribute to MM pathogenesis
- Results suggest the potential clinical application of DFX to the treatment of iron-overloaded and/or Pyk2/beta-catenin-driven MM.
- www.oncotarget.com/article/11830/text/
Doxycycline
- Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.
- ashpublications.org/blood/article/120/21/3138/102656/Doxycycline-Used-As-Post-Transplant-Antibacterial
